Clinical Trial Update: Aezea® (Cenersen) and Chemotherapy for AML Subjects ≥ 55 Years of Age With No Response to Frontline Induction Course [Phase 2]

View source ↗

Summary

A Phase 2 trial of Aezea (Cenersen) with chemotherapy for adults aged 55 and older with Acute Myeloid Leukemia who did not respond to frontline induction has be…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Aezea (Cenersen)

Snippet

Sponsor: Eleos, Inc. | Conditions: Acute Myelogenous Leukemia | Phase 2 | Status: WITHDRAWN